NasdaqGS:GHHealthcare
Guardant Health (GH) Soars 21% After Partnership With PathGroup
Guardant Health (GH) recently announced a key partnership with PathGroup and a clinical readout update, driving a 21% increase in their share price over the last quarter. The expanded reach of the Shield™ blood test through this partnership, alongside its inclusion in the NCCN guidelines, bolstered investor confidence. The company's achievements occur amid a broader market trend of record highs in major indices such as the S&P 500 and Nasdaq, buoyed by positive economic indicators and the...